Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 6,493,491 shares, a growth of 20.8% from the April 28th total of 5,373,898 shares. Based on an average daily volume of 1,012,440 shares, the short-interest ratio is currently 6.4 days.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 4.99% during trading on Friday, hitting $46.22. 1,626,169 shares of the stock were exchanged. The stock’s 50 day moving average price is $51.55 and its 200-day moving average price is $45.71. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $55.38. The company’s market cap is $4.07 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.23. During the same period in the previous year, the business posted ($0.22) EPS. On average, analysts predict that Neurocrine Biosciences will post ($2.46) EPS for the current year.

NBIX has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $80.00 price target on shares of Neurocrine Biosciences in a report on Tuesday, March 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $96.00 price target on shares of Neurocrine Biosciences in a report on Friday, February 10th. Oppenheimer Holdings Inc. set a $60.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a report on Saturday, April 8th. Bank of America Corp initiated coverage on shares of Neurocrine Biosciences in a report on Friday, May 5th. They issued a “buy” rating and a $70.00 price target for the company. Finally, Jefferies Group LLC increased their price target on shares of Neurocrine Biosciences from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, April 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and sixteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $67.75.

In related news, insider Haig P. Bozigian sold 13,065 shares of the stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $50.42, for a total value of $658,737.30. Following the completion of the transaction, the insider now owns 129,805 shares of the company’s stock, valued at approximately $6,544,768.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin Charles Gorman sold 19,596 shares of the stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $50.42, for a total transaction of $988,030.32. Following the completion of the transaction, the chief executive officer now directly owns 332,913 shares of the company’s stock, valued at approximately $16,785,473.46. The disclosure for this sale can be found here. Insiders have sold a total of 104,360 shares of company stock valued at $5,501,889 in the last three months. Insiders own 4.80% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Essex Investment Management Co. LLC raised its position in shares of Neurocrine Biosciences by 169.4% in the third quarter. Essex Investment Management Co. LLC now owns 35,361 shares of the company’s stock valued at $1,791,000 after buying an additional 22,234 shares in the last quarter. Asymmetry Capital Management L.P. raised its position in shares of Neurocrine Biosciences by 22.7% in the third quarter. Asymmetry Capital Management L.P. now owns 37,644 shares of the company’s stock valued at $1,906,000 after buying an additional 6,973 shares in the last quarter. NF Trinity Capital Hong Kong Ltd bought a new position in shares of Neurocrine Biosciences during the third quarter valued at approximately $3,190,000. KCG Holdings Inc. bought a new position in shares of Neurocrine Biosciences during the third quarter valued at approximately $1,003,000. Finally, Jana Partners LLC bought a new position in shares of Neurocrine Biosciences during the third quarter valued at approximately $4,872,000. Hedge funds and other institutional investors own 97.60% of the company’s stock.

WARNING: “Short Interest in Neurocrine Biosciences, Inc. (NBIX) Grows By 20.8%” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/05/26/short-interest-in-neurocrine-biosciences-inc-nbix-grows-by-20-8.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

12 Month Chart for NASDAQ:NBIX

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.